FDA approves first drug to slow Alzheimer's progression
Leqembi is an antibody designed to remove sticky deposits of a protein called amyloid beta from the brains of Alzheimer's patients.
The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023(photo credit: Eisai/Handout via REUTERS)ByREUTERS
